Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
Status:
Completed
Trial end date:
2016-03-11
Target enrollment:
Participant gender:
Summary
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for
Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in
subsequent efficacy studies.